Zebra Medical Vision announced that it appointed Ohad Arazi as its new CEO as the company as it looks to expand its footprint in the U.S.
Arazi’s appointment is set to be made effective on March 1, 2020, at which point he will succeed Zebra co-founder Eyal Gura, who will continue as board chairman. Arazi previously worked in healthcare IT and medical imaging at digital health firms such as McKesson Technology Solutions, Change Healthcare and Telus Health.
“Ohad Arazi’s appointment is a clear reflection of the strong vector the Zebra Medical Vision team has created, as we’re ready to take on the future after another strong year of product innovation, unique regulatory progress, and customer successes,” Gura said in a news release. “Zebra-Med is poised for major expansion in the medical imaging domain, and we’re confident that Ohad’s unique experience in turning innovative technologies into scalable and impactful products will drive significant growth for us.”
“Every CEO dreams of being able to drive the evolution of a company from such a position of material strength,” Arazi added. “As we expand our footprint in North America, the breadth of Zebra-Med’s products and compelling regulatory advantage will allow us to scale extraordinarily fast. I am thankful for the opportunity to lead one of the most exciting teams in healthcare today, and to leverage artificial intelligence to effect change for the medical imaging industry worldwide.”
Kibbutz Shefayim, Israel-based Zebra Medical recently won the fourth FDA clearance for its AI1 bundle of artificial intelligence technology.
The company’s HealthPNX artificial intelligence-powered pneumothorax alerting system designed to analyze chest X-rays won an FDA nod in May 2019 after its Coronary Calcium Scoring algorithm won clearance in July 2018.